Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market Size
| Study Period: | 2018- 2028 |
| Fastest Growing Market: | Middle East and North Africa |
| Largest Market: | North America |
| CAGR: | > 10 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and it's growth?
Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market Analysis
The Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market size was valued at USD 9,447.59 million in 2022, and is expected to reach USD 15,936.26 million by 2028, growing at a CAGR of 8.68% during the forecast period (2023-2028).
The Sodium-Dependent Glucose Cotransporter 2 market benefited from the COVID-19 pandemic. People with diabetes have a weakened immune system, which is exacerbated by COVID-19. Diabetes patients are more likely than non-diabetics to have significant problems. Diabetic medicine makers took care during COVID-19 to ensure that pharmaceuticals were delivered to diabetes patients with the assistance of local governments. "Since the start of COVID-19, our commitment to patients, our employees, and the communities where we operate has remained unchanged," NovoNordisk stated on their website. "We continue to supply our medicines and devices to people living with diabetes and other serious chronic diseases, safeguard the health of our employees, and take actions to support doctors and nurses as they work to defeat COVID-19."
SGLT-2 inhibitors, commonly known as gliflozins, are a kind of medication used to treat type 2 diabetes by lowering high blood glucose levels. SGLT-2 inhibitors have an important role in the management of cardiovascular risk factors such as blood pressure, glycemia, weight, cardiac function, and antiinflammatory action. Diabetic medications have been proposed as prospective treatments for diabetic people infected with SARS-CoV-2 during the COVID-19 epidemic. Technological advancements have increased over the period leading to several modifications either in the SGLT-2 inhibitors or the formulations being developed.
Therefore, due to increased prevalence and the aforementioned factors, the studied market is anticipated to witness growth over the analysis period.
Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Industry Segmentation
A family of glucose transporters is known as sodium-dependent glucose co-transporters (also known as sodium-glucose linked transporters or SGLT2). Only the proximal renal tubules express it, which is responsible for 90% of glucose reabsorption from tubular fluid. Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market Witnessed USD 9.4 billion in the current year and is anticipated to register a CAGR of over 10% during the forecast period. Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market is segmented into drugs (Invokana, Jardiance, Farxiga/Forxiga, and Suglat) and Geography. The report offers the value (in USD million) and volume (in Units million) for the above segments. We will provide a segment-wise breakdown (Value and Volume) for all the countries covered under the Table of Contents.
| Drug | ||||||
|
| Geography | |||||||||||||
| |||||||||||||
| |||||||||||||
| |||||||||||||
| |||||||||||||
|
Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market Trends
Jardiance is Leading the SGLT2 Market.
Jardiance, released globally in 2014, is a once-daily oral medication used to control blood glucose levels in people with Type 2 diabetes. Jardince is gaining sales compared to Invokana, with patients preferring this drug as it has a lower risk of cardiovascular diseases when compared to other SGLT2 drugs by helping the kidneys remove glucose from the bloodstream. Jardiance accounted for more than 30% of the sales in the global SGLT2 class of drugs in the current year. Jardiance is a prescription medicine used to lower blood sugar, diet, and exercise in adults with Type 2 diabetes. It reduces the risk of cardiovascular death in adults with Type 2 diabetes who also have known cardiovascular disease. Jardiance also reduces the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure, when the heart cannot pump enough blood to the rest of the body. It is not for people with Type 1 diabetes. Jardiance is a prescription drug used to lower blood sugar in individuals with Type 2 diabetes and to lessen the risk of cardiovascular death in adults with Type 2 diabetes who have known cardiovascular disease. It is also used in conjunction with diet and exercise. Heart attacks, strokes, and other cardiac disorders are all examples of cardiovascular illness. Jardiance has also been shown to lower A1C in persons with Type 2 diabetes who do not have cardiovascular disease (CV disease), diet, and exercise. Jardiance may aid some people in losing weight even though it wasn't designed to do so. In a study using Jardiance alone, the average weight loss at the 10 and 25 mg doses was 2.5% and 2.8%, respectively. Jardiance also assisted some individuals in slightly lowering systolic blood pressure, which is the highest number in the blood pressure reading, when used alone or in combination with metformin, even though it was not intended to do so.
To understand key trends, Download Sample Report
65% of the Market Share is Occupied by North America.
North America accounts for the highest Type 2 diabetic population. The growing global Type, 2 diabetes population promotes the growth of SGLT2 drugs. Prices are comparatively high in this region. Jardiance holds 50% of the market share in the US SGLT2 market. The American Diabetes Association Standards of Care has recommended empagliflozin (the active pharmaceutical ingredient in Jardiance) as the only diabetic drug that reduces the risk of cardiovascular death in adults with Type 2 diabetes. In the United States, the prevalence of diabetes has increased dramatically during the last two decades, driven by the increased prevalence of obesity and lifestyle changes. Diabetes ranks among the fast-growing chronic diseases in the United States. About 1.75 million US citizens are diagnosed with diabetes every year. The country also has the highest obese population, a prominent cause of Type 2 diabetes.
In addition to diet and exercise, SGLT2 inhibitors, a class of FDA-approved prescription medications, are used to lower blood sugar levels in people with Type 2 diabetes. Canagliflozin, dapagliflozin, and empagliflozin are examples of drugs that are SGLT2 inhibitors. Single-ingredient formulations and combinations with other diabetes drugs, such as metformin, are available. SGLT2 inhibitors lower blood sugar levels by stimulating the kidneys to remove sugar from the body through urine. Because it has not been established that SGLT2 inhibitors are safe and effective in patients with Type 1 diabetes, the FDA has not approved their use in this population. Most pharmaceutical companies view the United States as a premium market since they can charge more for their products than in other nations while still seeing high sales. Pharmaceutical businesses that sell pharmaceuticals benefit from the insurance program in the nation, which reimburses consumers for over 50% of the cost of prescription drugs. Due to the increased prevalence of obesity in the country, the United States is expected to lead the market throughout the forecast period.
To understand geography trends, Download Sample Report
Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Industry Overview
The Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market is highly consolidated, with a few significant manufacturers having a global market presence. The companies strengthen their market presence by getting approval in new forms.
Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market Leaders
Janssen Pharmaceuticals
Eli Lilly
Bristol Myers Squibb
AstraZeneca Pharmaceuticals
Astellas
*Disclaimer: Major Players sorted in no particular order
Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market News
- April 2022: Nippon Boehringer Ingelheim’s SGLT-2 inhibitor Jardiance (empagliflozin) obtained a label update from PMDA in Japan, allowing its use in patients with chronic heart failure with preserved ejection fraction (HFpEF) in addition to those with heart failure with reduced ejection fraction (HFrEF).
- February 2021: AstraZeneca’s Forxiga (dapagliflozin) was approved in China to reduce the risk of cardiovascular (CV) death and hospitalization for heart failure (hHF) in adults with heart failure (NYHA class II-IV) with reduced ejection fraction (HFrEF).
Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 Drug
5.1.1 Sodium - Glucose Co-transport -2 (SGLT-2) Inhibitor
5.1.1.1 Invokana (Canagliflozin)
5.1.1.2 Jardiance (Empagliflozin)
5.1.1.3 Farxiga/Forxiga (Dapagliflozin)
5.1.1.4 Suglat (Ipragliflozin)
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Rest of North America
5.2.2 Europe
5.2.2.1 France
5.2.2.2 Germany
5.2.2.3 Italy
5.2.2.4 Spain
5.2.2.5 United Kingdom
5.2.2.6 Russia
5.2.2.7 Rest of Europe
5.2.3 Latin America
5.2.3.1 Mexico
5.2.3.2 Brazil
5.2.3.3 Rest of Latin America
5.2.4 Asia-Pacific
5.2.4.1 Japan
5.2.4.2 South Korea
5.2.4.3 China
5.2.4.4 India
5.2.4.5 Australia
5.2.4.6 Vietnam
5.2.4.7 Malaysia
5.2.4.8 Indonesia
5.2.4.9 Philippines
5.2.4.10 Thailand
5.2.4.11 Rest of Asia-Pacific
5.2.5 Middle-East and Africa
5.2.5.1 Saudi Arabia
5.2.5.2 Iran
5.2.5.3 Egypt
5.2.5.4 Oman
5.2.5.5 South Africa
5.2.5.6 Rest of Middle-East and Africa
6. MARKET INDICATORS
6.1 Type-1 Diabetes Population
6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Eli Lilly
7.1.2 Janssen Pharmaceuticals
7.1.3 Bristol Myers Squibb
7.1.4 Boehringer Ingelheim
7.1.5 AstraZeneca
7.1.6 Astellas
- *List Not Exhaustive
7.2 MARKET SHARE ANALYSIS
7.2.1 Eli Lilly
7.2.2 Janssen Pharmaceuticals
7.2.3 Astellas
7.2.4 Boehringer Ingelheim
7.2.5 AstraZeneca
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market Research FAQs
What is the study period of this market?
The Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market is studied from 2018 - 2028.
What is the growth rate of Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market?
The Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market is growing at a CAGR of >10% over the next 5 years.
What is Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market size in 2018?
The Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market is valued at 9 Billion USD in 2018.
What is Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market size in 2028?
The Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market is valued at 14 Billion USD in 2028.
Which region has highest growth rate in Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market?
Middle East and North Africa is growing at the highest CAGR over 2021 - 2026.
Which region has largest share in Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market?
North America holds highest share in 2022.
Who are the key players in Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market?
Janssen Pharmaceuticals, Eli Lilly, Bristol Myers Squibb, AstraZeneca Pharmaceuticals, Astellas are the major companies operating in Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market.
Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Industry Report
Statistics for the 2023 Sodium-dependent Glucose Co-transporter 2 (SGLT 2) market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Sodium-dependent Glucose Co-transporter 2 (SGLT 2) analysis includes a market forecast outlook to for 2023 to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.
Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Report Snapshots
